Energy You Can Feel

NAD+ helps cells turn nutrients into usable energy and supports processes involved in cellular repair and stress response. Here is what NAD+ may support, what human research has found so far, and what remains unproven.

What is NAD+?

Nicotinamide adenine dinucleotide, usually called NAD+, is a helper molecule found in every living cell. It helps the body convert nutrients from food into ATP, the form of energy cells can use. NAD+ also supports systems involved in cellular repair, inflammation, and the response to physical and metabolic stress. [1]

NAD+ is not a stimulant in the traditional sense. It does not work like caffeine, and it is not simply an energy drink for the cells. Instead, it participates in the underlying chemistry that allows cells to use fuel and maintain normal function.

The body makes and recycles NAD+ through several pathways. Nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, are precursors that cells can use to make NAD+. A product labeled NAD+ is not the same as a product labeled NR or NMN. In the literature, “NAD” is sometimes used as shorthand for the NAD pool or for NAD+, the oxidized form. NADH is the reduced form. These molecules are related, but they are not interchangeable treatments. The ingredient, dose, formulation, and route all matter when interpreting the research. [2] [3]

What NAD+ may support

NAD+ has attracted interest because its role in cellular energy production is connected to several areas of health.

First, NAD+ supports normal mitochondrial function. Mitochondria are the structures that convert nutrients into usable energy. When people talk about NAD+ and energy, this is the biological foundation behind the conversation.

Second, NAD+ is involved in cellular repair and stress response. It supports enzymes that help cells respond to DNA damage, inflammation, and other forms of metabolic stress. Animal and human biomarker research suggests that NAD-related pathways may change with aging and illness, which is one reason NAD+ support is being studied in healthy aging and recovery. [1] [2]

Third, NAD+ research may be relevant to people who want to support energy, exercise recovery, sleep, or overall vitality. These are reasonable areas to study, but they are not interchangeable outcomes. A treatment that changes a blood NAD+ measurement may not produce the same effect on fatigue, physical function, or quality of life.

Human studies of oral NR and NMN have generally shown that these precursors can raise NAD-related metabolites in blood or cells and are usually well tolerated during the study periods. Effects on energy, cognition, sleep, and physical function have varied across studies and populations. These results provide useful context for NAD biology, but they do not establish that direct NAD+ treatment will produce the same result with every formulation or route. [2] [3]

In this context, biological activity means a measurable biochemical response. Studies have reported increases in blood or urine NAD+ or related metabolites, changes in blood measures of NAD metabolism, and shifts in markers related to oxidative stress, inflammation, and cellular metabolism. These findings suggest that a treatment is interacting with the pathway it is intended to affect. They are useful pharmacodynamic signals, but they are not the same as proving that a person has more energy, better cognition, or longer life.

What human research shows so far

Research remains limited regarding controlled human outcome trials showing that NAD therapy improves energy, fatigue, sleep, cognition, recovery, longevity, or quality of life. Much of the available evidence focuses on pharmacokinetics, biomarkers, tolerability, or short-term changes in laboratory measures. The studies are still useful because they show what researchers have been able to measure so far.

Grant and colleagues reported a small peer-reviewed pharmacokinetic pilot that infused direct NAD+ intravenously at 3 micromoles per minute for six hours. The researchers measured plasma and urine NAD+ and related metabolites, including nicotinamide, methyl-nicotinamide, ADPR, and NMN. Plasma NAD+ and related metabolites did not change during the first two hours. Later measurements showed changes in the plasma and urine NAD metabolome, including increased urinary NAD+ and methyl-nicotinamide. The study demonstrated measurable processing of infused NAD+, but it did not test energy, fatigue, cognition, sleep, exercise tolerance, recovery, or quality of life. [5]

A separate 2018 conference report described eight healthy adults ages 70 to 80 who received 1,000 mg of IV NAD+ daily for six days. The investigators reported higher NAD metabolome measures, lower markers of oxidative stress and inflammation, and increased expression or activity of SIRT1 and FOXO1 in peripheral blood cells. No major adverse effects were reported. This was a very small, open-label report without a control group, and it measured short-term biomarkers rather than patient-centered outcomes. It is best viewed as preliminary evidence of biological activity, not proof of a clinical benefit. [6]

A 2024 systematic review of 10 randomized NAD/NADH trials involving 489 participants found that its randomized evidence concerned oral NADH and NAD precursors rather than parenteral direct NAD+. [4] A separate 2026 systematic review identified 33 human NAD-related intervention studies, most involving oral NR or NMN. It found that NAD-related treatments can produce biological activity, while meaningful health outcomes remain variable. The review called for larger studies with clinically meaningful endpoints, particularly for injectable approaches. [7] [8]

Recent work has also questioned whether blood NAD+ simply declines with healthy aging in everyone. That does not disprove a targeted role for NAD+ support, but it does mean that routine “repletion” should remain an evidence question rather than an assumption. [9]

Subcutaneous, or subQ, treatment places medication into the fatty tissue just beneath the skin. It is a different way of delivering a treatment, so results from oral or IV research may not apply directly. Absorption, exposure over time, dose, formulation, and patient experience can all differ.

A 2026 preprint described a small phase 1 comparison of injectable NAD+ and NR across IV, intramuscular, and subcutaneous routes. In the subcutaneous conditions, pain and discomfort were the most common reported experiences. NAD+ and NR were described as comparably tolerated immediately after and following subcutaneous injections. No participants withdrew because of injection discomfort, and no severe or unexpected adverse events attributable to the test materials were reported. One moderate illness in the NAD+ group was judged unrelated to the intervention. The injection experiences were collected through open-ended, nonstandardized reports, and the study was small and had not completed peer review. It did not establish that subcutaneous NAD+ improves energy, fatigue, cognition, physical function, or longevity. [10]

This early information is encouraging from a basic tolerability standpoint, but it is not an efficacy study. The results from oral and IV NAD-related research may help inform the broader biology, but they cannot substitute for larger studies of the subcutaneous route itself.

Theoretical and practical risks

The risks of NAD therapy depend on the molecule being used, the dose, the formulation, the route, and the quality of the product. The short-term risks reported in human studies are generally route-specific. IV NAD+ has been associated with nausea, abdominal discomfort, flushing, cramping, chest pressure, and infusion intolerance, particularly when administered more quickly. Subcutaneous injections may cause pain, bruising, swelling, or local irritation. The small subcutaneous preprint did not identify severe or unexpected treatment-related events, but it was not large enough to establish long-term safety. [8] [10]

There are also theoretical biological risks with repeated or high-dose NAD augmentation. NAD+ participates in many cellular pathways, including DNA repair, immune signaling, cellular stress responses, and pathways involved in cell growth. Increasing NAD-related activity could therefore have different effects depending on the tissue, disease state, timing, and dose. Reviews have raised questions about possible interactions with senescent-cell inflammatory signaling and malignancy biology, but these concerns are based largely on mechanistic or preclinical evidence. They have not been established as clinical harms in people receiving NAD therapy. [2] [8]

Long-term safety is still uncertain, especially for people with active cancer, significant liver or kidney disease, multiple chronic conditions, or medications that affect related metabolic or inflammatory pathways. These populations have been underrepresented in the available studies, and potential drug interactions have not been well characterized. [8]

Finally, there is a practical risk of attributing all fatigue to NAD biology and delaying evaluation of more common or more serious causes. NAD therapy should be considered alongside, not instead of, attention to sleep, nutrition, medications, mood, anemia, thyroid disease, infection, and cardiopulmonary or metabolic conditions.

What NAD+ is not yet proven to do

NAD+ should not be presented as a cure for every form of fatigue. Low energy can be related to poor sleep, chronic stress, inadequate nutrition, depression or anxiety, medication effects, alcohol or other substances, anemia, thyroid or metabolic conditions, infection, hormonal changes, cardiopulmonary disease, or a period of unusually high physical or mental demand. Sleepiness, fatigue, and muscle weakness can also feel similar while having different causes. [11]

NAD+ is also not yet proven to reverse aging, extend human lifespan, prevent chronic disease, or reliably improve cognition in healthy adults. It should not replace sleep, adequate nutrition, physical activity, or evaluation of an underlying medical condition.

What this means in practice

NAD+ has a meaningful role in cellular energy production, repair, and stress response. Early human research supports continued interest in NAD-related therapies, but the current evidence is better at showing biological activity than proving a predictable patient-centered benefit.

For now, a thoughtful approach is to define the goal before treatment and track meaningful changes in energy, sleep, recovery, and daily function. The goal is not to promise that NAD+ explains every symptom. It is to understand where NAD+ support may be useful and evaluate its role carefully as the science continues to develop.

Medical-education disclaimer: This article is for general education and journal-club discussion, not individualized medical advice. Decisions about NAD-related therapies should be made with a qualified clinician who knows the patient’s medical history.